Foundation Medicine Announces Presentations at the 2015 San Antonio Breast Cancer Symposium

Dec 7, 2015

Foundation Medicine Announces Presentations at the 2015 San Antonio Breast Cancer Symposium

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Foundation Medicine, Inc. (NASDAQ:FMI) today announced that the company and its collaborators will present 10 poster presentations at the 2015 San Antonio Breast Cancer Symposium (SABCS) Annual Meeting taking place December 8-12, 2015 in San Antonio, Texas.

The company's molecular information products, FoundationOne® for solid tumors and FoundationOne® Heme for hematologic malignancies and sarcomas, provide a comprehensive genomic profile to identify the molecular alterations in a patient's cancer. The data to be presented at SABCS provide further supporting evidence of the clinical utility of Foundation Medicine's assays to identify emerging treatment options and inform efforts in treating breast cancer.

The schedule for poster presentations by Foundation Medicine and/or its collaborators is as follows:

Date and Time: Thursday, December 10, 2015, from 5:00-7:00 p.m. CT
Title: Non-Amplification ERBB2 Genomic Alterations in 5,605 Cases of Refractory and Metastatic Breast Cancer: an Emerging Opportunity for anti-HER2 Targeted Therapies
Poster Display Location: P3-07-05
Session: Prognostic and Predictive Factors: Response Predictions -- Biomarkers and Other Factors
Presenter: Jeffrey S. Ross MD, Chairman, Dept. of Pathology and Laboratory Medicine, Albany Medical College and Medical Director, Foundation Medicine, Inc.
Collaborators: Albany Medical College, Mayo Clinic Cancer Center, Washington University

Date and Time: Thursday, December 10, 2015, from 5:00-7:00 p.m. CT
Title: Evolution of Genomic Alterations on Endocrine Therapy and mTOR Inhibition in Estrogen Receptor (ER)-Positive Breast Cancer
Poster Display Location: P3-05-06
Session: 3 - Tumor Cell and Molecular Biology: Endocrine Therapy and Resistance
Presenter: Suleiman Alfred Massarweh, MD Associate Professor of Medicine(Oncology) at the Stanford University Medical Center
Collaborators: Stanford University Medical School, Stanford Cancer Institute, University of Kentucky, Markey Cancer Center

Date and Time: Friday, December 11, 2015, from 5:00-7:00 p.m. CT
Title: Lapatinib Reverses Endocrine Resistance in Select Patients with HER 2 negative, Hormone Positive Metastatic Breast Cancer
Poster Display Location: P5-14-06
Session: 5 - Advanced Endocrine Therapy
Presenter: Priyanka Sharma, MD, Associate Professor of Medicine at University of Kansas
Collaborators: University of Kansas Medical Center, Hays Medical Center, Truman Medical Center

Date and Time: Friday, December 11, 2015, from 5:00 -7:00 p.m. CT
Title: Individualized molecular analyses guide efforts in breast cancer with comprehensive genomic profiling of tissue and plasma tumor DNA
Poster Display Location: PD6-08
Session: Translational Genomics
Presenter: Heather Parsons, MD, MPH Instructor in Medicine, Harvard Medical School at Dana Farber Cancer Institute
Collaborators: Dana-Farber Cancer Institute, Johns Hopkins Medical Institutions (JHMI)

Date and Time: Saturday, December 12, 2015, from 7:30-9:00 a.m. CT
Title: Comprehensive Genomic Profiling of Clinically Advanced Mucinous Carcinoma of the Breast
Poster Display Location: P6-03-12
Session: Tumor Cell and Molecular Biology: Genomics
Presenter: Jeffrey S. Ross MD, Chairman, Dept. of Pathology and Laboratory Medicine, Albany Medical College and Medical Director, Foundation Medicine, Inc.
Collaborators: Albany Medical College

Date and Time: Saturday, December 12, 2015, from 7:30-9:00 a.m. CT
Title: Clinicopathologic Characterization and Comprehensive Genomic Profiling (CGP) of Advanced Breast Cancer Patients with Fibroblast Growth Factor Receptor (FGFR) Alterations
Poster Display Location: P6-07-06
Session: 6 - Tumor Cell and Molecular Biology: Genetics -- Somatic Changes
Presenter: Ricardo Alvarez, MD, MSc , Director of Cancer Research & Breast Medical Oncologist, Southeastern Regional Medical Center, CTCA
Collaborators: Cancer Treatment Centers of America

Date and Time: Saturday, December 12, 2015, from 7:30-9:00 a.m. CT
Title: EGFR Genomic Alterations in 5,605 Cases of Refractory and Metastatic Breast Cancer
Poster Display Location: P6-03-02
Session: 6 - Tumor Cell and Molecular Biology: Genetics -- Somatic Changes
Presenter: Siraj M. Ali MD, PhD, Director Clinical Development, Foundation Medicine
Collaborators: Houston Methodist Hospital

About Foundation Medicine

Foundation Medicine (NASDAQ:FMI) is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient's unique cancer. The company's clinical assays, FoundationOne® for solid tumors and FoundationOne® Heme for hematologic malignancies and sarcomas, provide a comprehensive genomic profile to identify the molecular alterations in a patient's cancer and match them with relevant targeted therapies and clinical trials. Foundation Medicine's molecular information platform aims to improve day-to-day care for patients by serving the needs of clinicians, academic researchers and drug developers to help advance the science of molecular medicine in cancer. For more information, please visit http://www.FoundationMedicine.com or follow Foundation Medicine on Twitter (@FoundationATCG).

Foundation Medicine® and FoundationOne® Heme are registered trademarks of Foundation Medicine, Inc.

Cautionary Note Regarding Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding presentations by Foundation Medicine and its collaborators of abstracts at the 2015 San Antonio Breast Cancer Symposium (SABCS) Annual Meeting and the ability of Foundation Medicine's clinical assays to identify genomic alterations, inform the treatment of patients and improve clinical outcomes. All such forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include the risks that Foundation Medicine's clinical assays do not perform in the same manner as the data and information presented at SABCS and the risks described under the caption "Risk Factors" in Foundation Medicine's Quarterly Report on Form 10-Q for the quarter ended March 31, 2015, which is on file with the Securities and Exchange Commission, as well as other risks detailed in Foundation Medicine's subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Foundation Medicine undertakes no duty to update this information unless required by law.

 

Media Contact:
Dan Budwick, Pure Communications, Inc.
973-271-6085
dan@purecommunicationsinc.com
or
Investor Contact:
Kimberly Brown
617-418-2215
ir@foundationmedicine.com
or
Matt Clawson
949-370-8500
matt@purecommunicationsinc.com

Source: Foundation Medicine

 

 

News Provided by Acquire Media